The Role of Immunotherapy in Breast Cancer

During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

One new frontier of cancer detection is emerging: metabolomics.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.